BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2.
The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 268.2K |
| Three Month Average Volume | 5.4M |
| High Low | |
| Fifty-Two Week High | 213.83 USD |
| Fifty-Two Week Low | 126.9681 USD |
| Fifty-Two Week High Date | 11 Sep 2023 |
| Fifty-Two Week Low Date | 19 Apr 2024 |
| Price and Volume | |
| Current Price | 191.78 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 11.21% |
| Thirteen Week Relative Price Change | 20.38% |
| Twenty-Six Week Relative Price Change | 5.70% |
| Fifty-Two Week Relative Price Change | -26.26% |
| Year-to-Date Relative Price Change | -10.21% |
| Price Change | |
| One Day Price Change | -3.39% |
| Thirteen Week Price Change | 28.84% |
| Twenty-Six Week Price Change | 16.22% |
| Five Day Price Change | -1.05% |
| Fifty-Two Week Price Change | -7.60% |
| Year-to-Date Price Change | 6.33% |
| Month-to-Date Price Change | 15.13% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 36.95203 USD |
| Book Value Per Share (Most Recent Quarter) | 34.60832 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 36.35515 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 34.05607 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -7.53076 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 23.55439 USD |
| Revenue Per Share (Trailing Twelve Months) | 29.49123 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -8.44649 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.07611 USD |
| Normalized (Last Fiscal Year) | -10.70628 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -8.44649 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.0323 USD |
| Including Extraordinary Items (Last Fiscal Year) | -8.44649 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.07611 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 33.16078 USD |
| Cash Per Share (Most Recent Quarter) | 26.65497 USD |
| Cash Flow Per Share (Last Fiscal Year) | -7.60661 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.0776 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -12.91595 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -134 |
| Cash Flow Revenue (Trailing Twelve Months) | -44 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -15.20% |
| Pretax Margin (Last Fiscal Year) | -33.59% |
| Pretax Margin (5 Year) | -117.26% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 84.55% |
| Gross Margin (Trailing Twelve Months) | 76.13% |
| Gross Margin (5 Year) | 83.19% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -34.36% |
| Operating Margin (Trailing Twelve Months) | -16.90% |
| Operating Margin (5 Year) | -115.60% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -35.86% |
| Net Profit Margin (Trailing Twelve Months) | -16.91% |
| Net Profit Margin (5 Year) | -120.76% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 4.87% |
| Tangible Book Value (5 Year) | 15.59% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 56.09% |
| Revenue Growth (3 Year) | 65.47% |
| Revenue Change (Trailing Twelve Months) | 71.01% |
| Revenue Per Share Growth | 45.80% |
| Revenue Growth (5 Year) | 99.67% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 33.46% |
| Total Debt (5 Year) | 34.89% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 68.43% |
| EPS Change (Trailing Twelve Months) | 69.54% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 6 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,555,727,000 |
| Net Debt (Last Fiscal Year) | -2,288,416,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 8 |
| Price to Sales (Trailing Twelve Months) | 7 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 6 |
| Long Term Debt to Equity (Most Recent Quarter) | 6 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | 2 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -1,753,714,000 |
| Free Cash Flow (Trailing Twelve Months) | -1,356,156,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 25 |
| Total Debt to Equity (Most Recent Quarter) | 31 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -14.47% |
| Return on Assets (Trailing Twelve Months) | -9.15% |
| Return on Assets (5 Year) | -26.72% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -22.26% |
| Return on Equity (Trailing Twelve Months) | -14.62% |
| Return on Equity (5 Year) | -38.83% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -19.80% |
| Return on Investment (Trailing Twelve Months) | -12.94% |
| Return on Investment (5 Year) | -33.85% |